SCHEMBL13020342

SCHEMBL13020342

CC(C)N1CC(n2cc(-c3ccc(Cl)cc3)c3c(N)ncnc32)C1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRC P12931 12/20 0.56
RIPK2 O43353 6/20 0.55
HCK P08631 1/20 0.55
LCK P06239 3/20 0.55
KDR P35968 3/20 0.55
TEK Q02763 3/20 0.55
EGFR P00533 8/20 0.55
ABL1 P00519 7/20 0.55
ABL2 P42684 7/20 0.55
KDM4E B2RXH2 1/20 0.50
MEN1 O00255 1/20 0.50
RGS12 O14924 1/20 0.50
NPC1 O15118 1/20 0.50
GMNN O75496 1/20 0.50
ALDH1A1 P00352 1/20 0.50
LMNA P02545 1/20 0.50
TP53 P04637 1/20 0.50
CYP1A2 P05177 1/20 0.50
FYN P06241 1/20 0.50
LYN P07948 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13020344 0.83 RET (0.62) SRCRIPK2LCKKDRTEK
SCHEMBL13020005 0.82 SRC (0.78) SRCRIPK2LCKKDRTEK
SCHEMBL13020153 0.81 SRC (0.58) SRCRIPK2HCKLCKKDR
SCHEMBL13020337 0.80 SRC (0.72) SRCRIPK2LCKKDRTEK
SCHEMBL13020345 0.79 SRC (0.56) SRCRIPK2EGFR
SCHEMBL13020100 0.78 KDR (0.68) SRCLCKKDRTEKFYN
SCHEMBL13020346 0.78 RET (0.52) SRCRIPK2HCKKDREGFR
SCHEMBL13840215 0.78 SRC (0.73) SRCEGFRABL1ABL2
SCHEMBL3784297 0.78 SRC (0.58) SRCRIPK2HCKLCKKDR
SCHEMBL13020339 0.77 RET (0.66) SRCRIPK2KDREGFRABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100331297-A1 MODULATION OF PROTEIN TRAFFICKING FOLDRX PHARMACEUTICALS, INC. (US) 2010-12-30 US disclosed
US-20100331297-A1 MODULATION OF PROTEIN TRAFFICKING FOLDRX PHARMACEUTICALS, INC. (US) 2010-12-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100331297-A1 MODULATION OF PROTEIN TRAFFICKING RAB1A, COPB1, GOLT1B SRC 1332/4885RIPK2 2849/4885HCK 3136/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.